F
Fairmount Funds Management LLC
+ HoldingFTH
+23.55%
3M Return
$33.840
+0.102 (+0.30%)At close
Loading chart…
- High
- 35.235
- Open
- 33.500
- VWAP
- 33.95
- Vol
- 288.30K
- Mkt Cap
- —
- Low
- 32.780
- Amount
- 9.79M
- EV/EBITDA, TTM
- 0.00
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.
AI analysis of Faeth Therapeutics, Inc (FTH)
buyFaeth Therapeutics appears to be a good buy right now, with a current price of $33.84 and a strong 5-day change of +5.75%. The RSI is at 63.079, suggesting bullish momentum. Additionally, analysts project a price target of $56, which represents a potential upside of approximately 65% from the current price. However, the main risk is the significant net loss reported for Q1 2026, which was -$170.2 million, indicating ongoing financial challenges that investors should monitor closely.
Valuation Metrics
The current forward P/E ratio for Faeth Therapeutics, Inc (FTH) is 0.00, compared to its 5-year average forward P/E of .
Whales holding FTH
Events Timeline
News
5.008-28NewsfilterFaeth Therapeutics Grants Stock Options to New Employees
- 8.508-17Newsfilter
Faeth Receives FDA Fast Track Designation for PIKTOR
- 5.008-14Newsfilter
Faeth Therapeutics Appoints New Executives to Enhance Operations and Investor Relations
9.508-10NASDAQ.COMFaeth Therapeutics Shares Surge 18% on Pipeline Update
- 8.508-07Newsfilter
Faeth Therapeutics to Present PIKTOR Data at 2026 Cancer Summit
FTH FAQ — answered by Alphio AI
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib. It operates in the Healthcare sector.
Faeth Therapeutics appears to be a good buy right now, with a current price of $33.84 and a strong 5-day change of +5.75%. The RSI is at 63.079, suggesting bullish momentum. Additionally, analysts project a price target of $56, which represents a potential upside of approximately 65% from the current price. However, the main risk is the significant net loss reported for Q1 2026, which was -$170.2 million, indicating ongoing financial challenges that investors should monitor closely.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.